CD274 and non-small cell lung carcinoma: In non-small-cell lung cancer patients who received nivolumab treatment, a higher mutational burden (≥10 mutations per Mb) was found to be associated with better progression-free survival (PFS), regardless of PD-L1 expression level [81].